Written by Elizabeth Cairns, Mobilize Recovery Special Projects, and reviewed by Code Recover Peer Advisors, August 2026

Peer recovery support specialist Greg Jacobs talks about language and stigma.

Understanding the Disease Model

A common misconception about opioid patients is that insufficient willpower is the issue, or that their substance use reflects a lack of morals. The patients themselves may feel frustrated or hopeless about failed past attempts to control their use. Part of your role is to help them, and the clinicians treating them, understand that opioid use disorder (OUD) is a chronic medical condition, not a moral failing. Just like diabetes or hypertension, OUD involves physical changes in the body, specifically the brain.

Opioids hijack the brain's reward system, flooding it with dopamine. Over time, the brain stops making its own dopamine and relies on the drug just to feel "normal." When the drug is taken away, the brain panics, causing severe withdrawal symptoms that feel life-threatening. This cycle of use, withdrawal, and craving is physiological. It is not about making bad choices; it is about a brain that has been rewired.

Undoing this rewiring is a process that cannot be immediately solved in the ED, but initiating medication for OUD to stabilize the patient physiologically (the clinician handles this) and then connecting them to resources to help them continue the process (this is the peer’s role) is the best way to start them on a healthier path.

Available Medications 

Medication for Opioid Use Disorder (MOUD) is the gold standard for treatment. It stabilizes brain chemistry so the patient can focus on their life, not managing the discomfort of withdrawal. Here is how to explain the three FDA-approved options to a patient:

• Methadone (Full Agonist): Think of this as fully satisfying the brain's hunger for opioids without the high or dangerous side effects when dosed correctly. It occupies the opioid receptors completely. It is usually dispensed daily at a specialized clinic (OTP).
• Buprenorphine/Suboxone (Partial Agonist): This medication fills the opioid receptors enough to stop withdrawal and cravings but has a ceiling effect that makes it much harder to overdose. It is often started in the ED and can be prescribed by regular doctors for pickup at a pharmacy.
• Naltrexone/Vivitrol (Antagonist): This blocks the opioid receptors entirely. It acts like a shield, preventing any opioid from having an effect. However, a patient must be fully detoxed (opioid-free for 7-10 days) before starting it to avoid triggering immediate withdrawal. For this reason it is not often prescribed in the ED. It can be a useful tool for managing cravings after detox, as it is available as a monthly injection or a daily oral dose. It is also useful and approved for patients with alcohol use disorder.  

The Myth of "Substituting One Drug for Another"

You will hear this line a lot — from patients, from family members, sometimes from clinical staff: MOUD is just "trading one drug for another." It's rooted in stigma, misinformation, and a misunderstanding of how addiction actually works in the brain. When you hear it, you don't need to get defensive, you just need the receipts. Here's how to answer the most common versions of this argument.

• "They're just dependent on a new drug." Push back gently: dependence and addiction aren't the same thing. Dependence means the body needs medication to function normally, and plenty of chronic conditions work that way. Addiction means compulsive use despite harm. MOUD restores brain function so patients can live productive lives; illicit opioid use does the opposite. And the stakes are real — people on methadone or buprenorphine cut their risk of dying, from any cause and from overdose specifically, compared with being off treatment. (source)
• "Real recovery means total abstinence." You can say it plainly: SAMHSA is explicit that patients taking FDA-approved medication for OUD are considered to be in recovery. (source) MOUD stabilizes the patient without a high, which is what actually lets someone begin the social and emotional work of recovery.
• "These drugs are just as dangerous as what they were using." Illicit opioid use is unsupervised and carries a high risk of overdose. Methadone and buprenorphine are approved, evidence-based treatments with excellent safety profiles when taken as prescribed. (source)
• "They'll just sell it or misuse it." This one you can meet head-on with numbers. Across a review of 17 studies, most people using non-prescribed buprenorphine weren't doing it to get high; they were managing withdrawal or trying to stay off other opioids on their own. (source) One Rhode Island survey put actual numbers on it: 12% used diverted buprenorphine to get high, versus 40% managing withdrawal and 39% self-treating their OUD. (source) Diversion is mostly a symptom of people not being able to get treatment any other way, not a reason to withhold it.
• "Opening the floodgates" — offering MOUD will bring in a population we can't manage. MOUD is the gold standard of care and improves outcomes for a population that's historically been hard to treat. It's also a good investment: ED-initiated buprenorphine has been shown to be more cost-effective than referral alone. (source)

Overdose Prevention: Meeting People Where They Are

Recovery looks different for everyone. For some, it means total abstinence. For others, it means using safer practices to stay alive until they are ready to make changes. Overdose prevention strategies—like carrying naloxone, and using fentanyl test strips—are valid and necessary parts of the continuum of care. We do not judge a diabetic for eating a slice of cake; we help them manage their insulin. Similarly, we support OUD patients in staying safe, regardless of where they are in their journey.